Navigation Links
Lilly Quality Leader Walsh Appointed to Company's Executive Committee
Date:7/1/2011

INDIANAPOLIS, July 1, 2011 /PRNewswire/ -- Fionnuala Walsh, Ph.D., will join the executive committee of Eli Lilly and Company (NYSE: LLY) on July 1.

Walsh will continue in her current role as Lilly's senior vice president of global quality, reporting to John Lechleiter, Ph.D., chairman, president, and CEO, and working to ensure Lilly continues to maintain high quality standards across its worldwide operations.

Walsh is a recognized thought leader in the quality industry, often speaking about Lilly's sustainable, integrated quality system and the company's commitment to maintaining a quality culture. Her presence on the company's most senior governance committee is expected to further underscore Lilly's ongoing commitment to quality.

A native of Ireland, Walsh earned a bachelor's degree and doctoral degree in chemistry from University College Dublin. She joined Lilly's Kinsale, Ireland, manufacturing site in 1988 as a technical services chemist. After numerous positions there, she moved into a role as global quality leader at the Lilly Corporate Center in Indianapolis in 2002.

In January 2003, Walsh was named executive director of quality for U.S. drug product and Lilly Technology Center operations. In July 2005, she was named vice president of global quality operations, and, in June 2007, she was named senior vice president of global quality.

About Eli Lilly and Company

Lilly, a leading, innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers—through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Multiple Myeloma ...  report to their offering.       ... Multiple Myeloma Market and Competitive Landscape Highlights ... pipeline products, Multiple Myeloma epidemiology, Multiple Myeloma ...
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
(Date:5/3/2016)... May 3, 2016 BioNovus Innovations LLC ... for Advancing Medical Innovation (IAMI) today announced a ... diagnostics and medical devices. An agreement ... rights to license, develop and commercialize medical innovations ... "This partnership represents a significant advance in ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... The RIDER Institute ... development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all 18 ... 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, we are ...
(Date:5/4/2016)... New York, N.Y. (PRWEB) , ... May 04, 2016 , ... ... Inaugural Spiritual Care Day to recognize chaplains for their valuable support to patients and ... observed annually on May 10. , To mark Spiritual Care Day, SCA has sent ...
(Date:5/4/2016)... ... , ... A new collaboration will give more researchers access to the largest ... analytics leader SAS will provide researchers worldwide with data management and analytics tools to ... , The DCRI and SAS share the goal of greater transparency and openness ...
(Date:5/4/2016)... ... May 04, 2016 , ... Washington Wellness Center today announced its ... Jersey residents. What started out as an idea to provide a holistic approach ... to healthcare. , Developed by Dr. David Swanekamp, Chiropractic Physician , the wellness ...
(Date:5/4/2016)... ... 2016 , ... Dr. Elyson and Dr. Assili, dentist in Northridge , ... tooth removal, a common dental procedure, is performed for many adolescents and young adults ... in risks of complications. By providing wisdom tooth removal surgery at their office, Dr. ...
Breaking Medicine News(10 mins):